New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved anti-obesity medications.

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.

President Trump has put all the federal health agencies on ice until his administration staffs up. One of those agencies that shouldn’t get lost in the mix: the Centers for Medicare and Medicaid Services.

Premier has called on CMS to enhance Medicare Advantage and Part D policies for 2026, emphasizing policies to protect access to care, particularly in rural areas.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

An expanding prohibition on third-party financial guarantees could lead to more nursing home using lawsuits to collect unpaid debt.

The National Community Pharmacists Association has told CMS that more than 90% of independent pharmacies may choose to stop stocking drugs included in the Medicare Drug Price Negotiation Program due to financial losses that could threaten their viability.

CMS issued the industry-wide ratings the next month. Among large insurers, UnitedHealthcare experienced one of the most dramatic drops in scores. In its lawsuit, the UnitedHealth Group subsidiary alleged the decline improperly cost the company “tens of millions” in federal payments.

Several VERIFY readers asked us if these posts are true. Trump rescinded an executive order that required the Center for Medicare and Medicaid Services (CMS) to develop and test ways to lower drug prices for people on Medicare and Medicaid. Since former ...

The Centers for Medicare & Medicaid Services has changed course on plans to appeal a court ruling that determined it must recalculate UnitedHealthcare's Medicare Advantage star ratings.

Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of